儿童慢性髓性白血病伊马替尼治疗药物监测:真实世界数据
该研究在真实世界条件下对66例儿童慢性髓性白血病患者进行伊马替尼治疗药物监测,分析246份血样。伊马替尼及去甲伊马替尼中位谷浓度分别为1017 ng/mL和269 ng/mL,与处方剂量显著相关。伊马替尼谷浓度>1000 ng/mL与第3个月和第6个月达到主要分子学反应相关,但差异仅在第3个月显著。
要点
- 13岁以下患儿伊马替尼中位剂量暴露较年长患者高43 mg/m2(p<0.0001)。
- 伊马替尼谷浓度>1000 ng/mL组第3个月和第6个月达到主要分子学反应的比例均为63%。
- 66例患者中30例报告125例不良事件,以胃肠道和肌肉骨骼症状为主。
核心结论
- 治疗药物监测是真实世界条件下管理儿童慢性髓性白血病的一种简单快速的附加工具。
研究设计与样本
- 研究在真实世界条件下收集66例儿童慢性髓性白血病患者的246份血样及治疗药物监测相关数据,计算个体剂量暴露,采用高效液相色谱-串联质谱法测定伊马替尼及去甲伊马替尼血浆谷浓度,并记录不良事件。
主要发现
- 个体中位伊马替尼剂量暴露为253 mg/m2(范围128-504),13岁以下患儿较年长患者接受的中位剂量高43 mg/m2(p<0.0001)。
- 伊马替尼和去甲伊马替尼中位谷浓度分别为1017 ng/mL(范围51-3976)和269 ng/mL(范围21-981),与处方剂量显著相关。
- 246次访视中5次确认不依从,涉及66例患者中的3例,均为13岁及以上患者,表现为伊马替尼谷浓度极低。
- 伊马替尼谷浓度>1000 ng/mL与达到主要分子学反应的相关性显示,第3个月和第6个月分别有63%(N=24/37,N=27/43)患者达到该里程碑;较低浓度队列中分别仅23%和50%达到,差异仅在第3个月显著。
- 66例患者中30例报告125例不良事件,以胃肠道和肌肉骨骼症状为主;9.3%的不良事件相关伊马替尼谷浓度≥3000 ng/mL。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Imatinib (IMA) therapy for paediatric chronic myeloid leukemia (pCML) requires age-dependent dose adjustments. Assessment of therapeutic drug monitoring (TDM) under 'real-world' conditions was performed. Collection of blood and TDM-relevant data, calculation of individual dosage exposure, measurement of plasma Cmin (IMA, Nor-IMA) by HPLC/MS-MS and recording of adverse event (AE). Two hundred and forty-six specimens from 66 patients were analysed. Individual median IMA dosage exposure was 253 mg/m2 (range: 128-504). Children <13 years received a median of 43 mg/m2 more than older patients (p < 0.0001). Median Cmin of IMA and Nor-IMA was 1017 ng/mL (range: 51-3976) and 269 ng/mL (range: 21-981), respectively, correlating significantly with the prescribed dose. At 5/246 visits, non-adherence was confirmed by very low IMA Cmin in 3/66 patients, all ≥13 years old. Correlation of IMA Cmin >1000 ng/mL with achieving OMR demonstrated in each 63% (N = 24/37, N = 27/43, respectively) patients at months 3 and 6. In the cohort with lower levels, only 23% and 50%, respectively, achieved these milestones. This difference was significant only at month 3. Of 66 patients, 30 reported 125 AEs with gastrointestinal and musculoskeletal as leading complaints. In 9.3% of AEs, the correlated IMA Cmin was ≥3000 ng/mL. TDM is a simple and rapid additional tool for managing pCML under 'real-world conditions'.
引用
- Suttorp M, Sembill S, Lensker P, et al. Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting. Br J Haematol. 2025. PMID: 40059620. doi:10.1111/bjh.20047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。